Oncternal Therapeutics Inc Stock, NASDAQ:ONCT
12230 El Camino Real, Suite 300, San Diego, California 92130
United States of America
Number of Employees: 14
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.